Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms

The American Journal of Medicine
Bart Staels

Abstract

The mechanism of action of empagliflozin in reducing the risk of adverse cardiovascular outcomes vs placebo in patients with type 2 diabetes mellitus and a high risk of cardiovascular disease in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial is currently unknown. An antiatherosclerotic effect is considered unlikely given the speed of the observed decrease in cardiovascular mortality. Hemodynamic effects, such as reductions in blood pressure and intravascular volume, and involving osmotic diuresis, may provide a more plausible explanation. Metabolic effects, such as cardiac fuel energetics, and hormonal effects, such as increased glucagon release, may also contribute to the results observed during EMPA-REG OUTCOME. This review discusses the main hypotheses suggested to date.

References

Nov 8, 2003·Hypertension·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Jul 4, 2007·Circulation·Ernesto L SchiffrinJohannes F E Mann
Dec 14, 2007·European Journal of Heart Failure·Erik LipsicWiek H van Gilst
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
Sep 14, 2010·Korean Diabetes Journal·Udayakumar Karunakaran, Nam Ho Jeoung
Oct 30, 2010·Circulation Research·Ferdinando Giacco, Michael Brownlee
Feb 2, 2012·Endocrinology·B J JonesS R Bloom
Jan 17, 2013·Postgraduate Medicine·Carlos Campos
Feb 21, 2013·Current Atherosclerosis Reports·Saloua El MessaoudiNiels P Riksen
May 15, 2013·Diabetes, Obesity & Metabolism·H J Lambers HeerspinkJ List
Jun 12, 2013·Postgraduate Medicine·Agata PtaszynskaJames List
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Oct 18, 2013·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jens LutzKlaus Thürmel
Oct 22, 2013·Trends in Endocrinology and Metabolism : TEM·John C Newman, Eric Verdin
Nov 30, 2013·Pharmacology & Therapeutics·Sujith Dassanayaka, Steven P Jones
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Apr 30, 2014·Nature Reviews. Cardiology·Fan JiangCheng Zhang
Jun 8, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Michelle C OddenCarmen A Peralta
Jun 21, 2014·The Lancet. Diabetes & Endocrinology·Martin RidderstråleUNKNOWN EMPA-REG H2H-SU trial investigators
Sep 7, 2014·Diabetes Research and Clinical Practice·John C Newman, Eric Verdin
Dec 4, 2014·Current Opinion in Nephrology and Hypertension·Marko Škrtić, David Z I Cherney
Jan 16, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Silvio E InzucchiOdd Erik Johansen
Feb 11, 2015·JAMA : the Journal of the American Medical Association·Connor A EmdinAnushka Patel
Apr 19, 2015·European Heart Journal·Petar M Seferović, Walter J Paulus
Jun 4, 2015·The New England Journal of Medicine·Rodney A HaywardUNKNOWN VADT Investigators
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Nov 7, 2015·Journal of Diabetes and Its Complications·Ralph A DeFronzo

❮ Previous
Next ❯

Citations

May 21, 2017·The American Journal of Medicine·Son V Pham, Robert Chilton
Apr 29, 2018·Heart Failure Reviews·Joaquim Silva CustodioLeonardo Roever
Mar 13, 2018·Circulation·Karin RådholmBruce Neal
Nov 27, 2019·Cardiac Failure Review·Muhammad Shahzeb Khan, Javed Butler
May 9, 2019·Journal of Cardiovascular Pharmacology and Therapeutics·Aparna P SajjaAnkur Kalra
Aug 15, 2019·Heart Failure Reviews·Petra Grubić RotkvićLuka Rotkvić
Aug 29, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Dhiren K Patel, Jodi Strong
Jul 27, 2020·Endocrinology, Diabetes & Metabolism·Oliver SchnellAntonio Ceriello
Aug 28, 2020·World Journal of Diabetes·Petra Grubić RotkvićIvana Ćelap
May 3, 2019·Journal of Diabetes·Muhammad Shahzeb Khan, Javed Butler
Feb 4, 2021·Heart Failure Reviews·Maja NikolicVladimir Jakovljevic
Nov 6, 2020·International Journal of Nephrology and Renovascular Disease·George Vasquez-Rios, Girish N Nadkarni
Dec 5, 2020·Heart Failure Reviews·Amir FathiJagdeep S Singh
Nov 22, 2017·Journal of Diabetes and Its Complications·Elaine NguyenErin R Weeda
Oct 9, 2021·British Journal of Clinical Pharmacology·Hani EssaRajiv Sankaranarayanan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.